United therapeutics corporation (UTHR)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08
Revenues:
Total revenues

1,448,800

1,627,800

1,725,300

1,598,800

1,460,600

1,279,500

1,106,944

906,123

741,094

591,702

357,636

270,005

Other

-

-

-

-

5,200

9,000

10,040

9,953

2,089

1,197

1,244

-

Service sales

-

-

-

-

-

-

-

-

-

-

-

9,258

License fees

-

-

-

-

-

-

-

-

-

-

-

2,234

Operating expenses:
Cost of product sales

117,600

198,700

105,700

72,700

69,000

125,900

131,127

119,297

88,904

67,674

40,861

26,957

Research and development

1,182,600

357,900

264,600

147,600

245,100

242,500

299,348

173,387

180,015

165,306

120,368

239,181

Selling, general and administrative

-

-

-

316,800

452,700

381,300

394,010

201,746

156,482

188,606

171,894

94,306

Settlement of loss contingency

-

-

210,000

-

-

-

-

-

-

-

-

-

Cost of service sales

-

-

-

-

-

-

-

-

-

-

-

3,109

Total operating expenses

1,636,400

822,400

910,400

537,100

766,800

749,700

824,485

494,430

425,401

421,586

333,123

363,553

Operating income (loss)

-187,600

805,400

814,900

1,061,700

699,000

538,800

292,499

421,646

317,782

171,313

25,757

-82,056

Interest income

44,200

28,600

10,900

3,500

-

-

-

-

3,450

2,939

5,146

11,025

Interest expense

44,200

13,900

9,000

3,900

4,700

17,600

18,058

16,639

21,367

19,710

12,875

11,439

Equity loss in affiliate

-

-

-

-

-

-

-

-

-

-160

-141

-226

Other income, net

22,600

-7,700

2,300

-1,100

100

4,000

4,462

35,664

-748

769

736

-1,025

Other income (expense):
Gain on sale of intangible asset

-

-

-

-

350,000

-

-

-

-

-

-

-

Impairments of investments in privately-held companies

-

53,500

49,600

-

-

-

-

-

-

-

-

-

Total other income, net

22,600

-46,500

-45,400

-1,500

345,400

-13,600

-13,596

19,025

-18,665

-16,162

-7,134

-1,665

Income (loss) before income taxes

-165,000

758,900

769,500

1,060,200

1,044,400

525,200

278,903

440,671

299,117

155,151

18,623

-83,721

Income tax (expense) benefit

-60,500

169,700

351,600

346,500

392,800

185,100

104,343

136,229

81,874

43,945

-695

-34,394

Income from continuing operations

-

-

-

-

-

-

-

-

217,243

111,206

19,318

-

Income from discontinued operations, net of tax

-

-

-

-

-

-

-

-

7

-5,290

144

-

Gain on disposal of discontinued operations, net of tax

-

-

-

-

-

-

-

-

618

-

-

-

Income from discontinued operations

-

-

-

-

-

-

-

-

625

-5,290

144

-

Net income (loss)

-104,500

589,200

417,900

713,700

651,600

340,100

174,560

304,442

217,868

105,916

19,462

-49,327

Net income (loss) per common share:
Basic
Continuing operations (in dollars per share)

-

-

-

-

-

-

-

-

3.80

1.98

0.36

-

Discontinued operations (in dollars per share)

-

-

-

-

-

-

-

-

0.01

-0.09

0.01

-

Basic (in dollars per share)

-2.39

13.54

9.50

16.29

14.17

7.06

3.49

5.84

3.81

1.89

0.37

-1.08

Diluted
Continuing operations (in dollars per share)

-

-

-

-

-

-

-

-

3.66

1.87

0.34

-

Discontinued operations (in dollars per share)

-

-

-

-

-

-

-

-

0.01

-0.09

0.01

-

Diluted (in dollars per share)

-2.39

13.39

9.31

15.25

12.72

6.28

3.28

5.71

3.67

1.78

0.35

-1.08

Weighted average number of common shares outstanding:
Basic (in shares)

43,800

43,500

44,000

43,800

46,000

48,200

50,076

52,093

57,163

56,142

53,314

45,802

Diluted (in shares)

43,800

44,000

44,900

46,800

51,200

54,200

53,231

53,280

59,395

59,516

56,133

45,802

Net product sales
Total revenues

1,448,800

1,627,800

1,725,300

1,598,800

1,465,800

1,288,500

1,116,984

916,076

743,183

592,899

358,880

281,497